正在加载视频...
视频加载失败
We’ve closed a fully-subscribed $80 million financing to support our ongoing clinical trial in optic neuropathies and advancement of our Partial Epigenetic Reprogramming platform across multiple indications. Read more:
14,044 次观看 • 3 个月前 •via X (Twitter)
0 条评论
暂无评论
原始帖子的评论将显示在这里


